Floatz logo

Gamma4 Heavy Chain Homo Sapiens (1-446) [Vh (Homo Sapiens Ighv4-39*01 (96.0%) -(Ighd) -Ighj3*02 (100%), Cdr-Imgt [10.7.12] (26-35.53-59.98-109)) (1-120)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10, G4V4 Ch2 A1.3, A1.2 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 F1.3>A (234), L1.2>A (235), L92 (309) (231-340), Ch3 (341-445), Chs K2>Del (446)) (121-446)], (134-215')-Disulfide With Kappa Light Chain Homo Sapiens (1'-215') [V-Kappa (Homo Sapiens Igkv1-33*01 (96.8%) -Igkj4*01 (100%), Cdr-Imgt[6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')], Dimer (226-226'':229-229'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho)-K1Sv Cell Line Lacking The Glutamine Synthetase Gene (Gs-Ko), Glycoform Alfa

Diffuse Large B-Cell Lymphoma

Explore 253 assets in Diffuse Large B-Cell Lymphoma →
Floatz Rating
CC43/100
Confidence
Indicative
v0.2
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05039658CT.gov
Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
—Unknown———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Diffuse Large B-Cell Lymphoma

AssetSponsorPhaseRating
Gamma4 Heavy Chain Homo Sapiens (1-446) [Vh (Homo Sapiens Ighv4-39*01 (96.0%) -(Ighd) -Ighj3*02 (100%), Cdr-Imgt [10.7.12] (26-35.53-59.98-109)) (1-120)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10, G4V4 Ch2 A1.3, A1.2 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 F1.3>A (234), L1.2>A (235), L92 (309) (231-340), Ch3 (341-445), Chs K2>Del (446)) (121-446)], (134-215')-Disulfide With Kappa Light Chain Homo Sapiens (1'-215') [V-Kappa (Homo Sapiens Igkv1-33*01 (96.8%) -Igkj4*01 (100%), Cdr-Imgt[6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')], Dimer (226-226'':229-229'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho)-K1Sv Cell Line Lacking The Glutamine Synthetase Gene (Gs-Ko), Glycoform Alfa (this asset)Innovent Biologics (Suzhou) Co. Ltd.P1CC · 43
Vincristine SulfateNational Cancer Institute (NCI)P2/3A
MelphalanRuijin HospitalP4BBB
Axicabtagene CiloleucelRuijin HospitalP4BBB
AdriamycinBeth Israel Deaconess Medical CenterP4BBB
NivestimRuijin HospitalP3BBB
PrednisoneBeth Israel Deaconess Medical CenterP4BBB
Cyclosporin AFred Hutchinson Cancer CenterP3BBB
RituximabBeth Israel Deaconess Medical CenterP4BBB

+42 more in the Diffuse Large B-Cell Lymphoma cohort

Other indications for Gamma4 Heavy Chain Homo Sapiens (1-446) [Vh (Homo Sapiens Ighv4-39*01 (96.0%) -(Ighd) -Ighj3*02 (100%), Cdr-Imgt [10.7.12] (26-35.53-59.98-109)) (1-120)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10, G4V4 Ch2 A1.3, A1.2 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 F1.3>A (234), L1.2>A (235), L92 (309) (231-340), Ch3 (341-445), Chs K2>Del (446)) (121-446)], (134-215')-Disulfide With Kappa Light Chain Homo Sapiens (1'-215') [V-Kappa (Homo Sapiens Igkv1-33*01 (96.8%) -Igkj4*01 (100%), Cdr-Imgt[6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')], Dimer (226-226'':229-229'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho)-K1Sv Cell Line Lacking The Glutamine Synthetase Gene (Gs-Ko), Glycoform Alfa

IndicationSponsorPhaseRating
Cutaneous Melanoma—P1/2CCC · 48
Small Cell Lung Carcinoma—P1CC · 44
Non-Small Cell Lung Carcinoma—P1C · 39

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Gamma4 Heavy Chain Homo Sapiens (1-446) [Vh (Homo Sapiens Ighv4-39*01 (96.0%) -(Ighd) -Ighj3*02 (100%), Cdr-Imgt [10.7.12] (26-35.53-59.98-109)) (1-120)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10, G4V4 Ch2 A1.3, A1.2 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 F1.3>A (234), L1.2>A (235), L92 (309) (231-340), Ch3 (341-445), Chs K2>Del (446)) (121-446)], (134-215')-Disulfide With Kappa Light Chain Homo Sapiens (1'-215') [V-Kappa (Homo Sapiens Igkv1-33*01 (96.8%) -Igkj4*01 (100%), Cdr-Imgt[6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')], Dimer (226-226'':229-229'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho)-K1Sv Cell Line Lacking The Glutamine Synthetase Gene (Gs-Ko), Glycoform Alfa in Diffuse Large B-Cell Lymphoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/gamma4-heavy-chain-homo-sapiens-1-446-vh-homo-sapiens-ighv4-3901-960-ighd-ighj302-100-cdr-imgt-10712-26-3553-5998-109-1-120-homo-sapiens-ighg401-ng4ma-ch2-l92-g4v5-h-p10-g4v4-ch2-a13-a12-ch1-121-218-hinge-1-12-s10p-228-219-230-ch2-f13a-234-l12a-235-l92-309-231-340-ch3-341-445-chs-k2del-446-121-446-134-215-disulfide-with-kappa-light-chain-homo-sapiens-1-215-v-kappa-homo-sapiens-igkv1-3301-968-igkj401-100-cdr-imgt6310-27-3250-5289-98-1-108-homo-sapiens-igkc01-100-km3-a451-154-v101-192-109-215-dimer-226-226229-229-bisdisulfide-produced-in-chinese-hamster-ovary-cho-k1sv-cell-line-lacking-the-glutamine-synthetase-gene-gs-ko-glycoform-alfa-diffuse-large-b-cell-lymphoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →